BioSpace News Archive

Matrix Medical Network ® (Matrix) will be a key enabler in clinical trials of investigational COVID-19 vaccines conducted by the COVID-19 Prevention Network. Matrix Clinical Solutions, through an agre

CymaBay Therapeutics, Inc. announced that data from a Phase 2 study of seladelpar in nonalcoholic steatohepatitis will be delivered during The Liver Meeting Digital Experience™ 2020 of the American Association for the Study of Liver Diseases which will be held online November 13th – 16th.

CNS Pharmaceuticals, Inc., a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, announced that the Company’s GMP manufacturer partner NCK A/S, received a Certificate of Analysis for its Active Pharma Ingredient, clearing it for use in the production of Berubicin.

Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, announces the upcoming presentation of results from a prospective study using its Target Selector™ testing of the cerebrospi

BioLife Solutions, Inc. (NASDAQ: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced it has closed the acquisition of SciSafe

$3.36 million Commercialization Readiness Pilot award from the National Institute on Aging for completing the development of CogniMIR™, a blood-based test for early detection of mild cognitive impairment and Alzheimer’s disease

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI) , a medical device company focused on the design and development of robotic surgical technologies, announced the voting results from the Company’s Annual and Special Meeting of its Shareholders held on Wednesday, September 30, 2020. All of management’s nominees for election were duly elected as directors of the Company by the shareholders present or rep

Cyanotech® Corporation, (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health products, announces its launch of BioAstin® Hawaiian Astaxanthin® in a new delivery form, water dispersible powder, available in both 1% and 2% concentrations.

Arcturus Therapeutics Holdings Inc. announced that the Company will present virtually at the upcoming conference:

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to participate in the Jefferies Virtual Cell Therapy Summit in October 2020. Jefferies Virtual Cell Therapy Summit Tuesday, October 6, 2020 12:30 PM PT/3:30 PM ET This webcast will be made available on the Company’s website at w